Literature DB >> 2550666

Treatment of encephalomyocarditis virus-induced central nervous system demyelination with monoclonal anti-T-cell antibodies.

S Sriram1, D J Topham, S K Huang, M Rodriguez.   

Abstract

Infection of BALB/c mice with the M variant of encephalomyocarditis virus resulted in the development of a paralytic syndrome in 7 to 10 days. The paralysis was maximal during the period of viral clearance; most of the animals recovered from the initial deficit and showed no delayed recurrences. Pathologically, the white matter of brain and spinal cord showed well-demarcated areas of perivascular cuffing, demyelination, and, during recovery, remyelination by oligodendrocytes--all suggestive of postinfectious encephalomyelitis. Depletion of either the CD4 or CD8 subset of T cells in vivo with the appropriate monoclonal antibody, GK1.5 or 2.43, respectively, administered one day (24 h) prior to infection was sufficient to limit the development of the paralytic syndrome by 79% (GK1.5) and 82% (2.43).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2550666      PMCID: PMC251038          DOI: 10.1128/JVI.63.10.4242-4248.1989

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  Aggravation of coxsackievirus, group B, type 3-induced myocarditis and increase in cellular immunity to myocyte antigens in pregnant Balb/c mice and animals treated with progesterone.

Authors:  D C Lyden; S A Huber
Journal:  Cell Immunol       Date:  1984-09       Impact factor: 4.868

2.  Enzyme-linked immunosorbent assay for immunoglobulin G antibody to encephalomyocarditis virus.

Authors:  J D Shanley
Journal:  J Clin Microbiol       Date:  1980-11       Impact factor: 5.948

3.  Chronic central nervous system demyelination in mice after JHM virus infection.

Authors:  S A Stohlman; L P Weiner
Journal:  Neurology       Date:  1981-01       Impact factor: 9.910

4.  Murine central nervous system infection by a viral temperature-sensitive mutant: a subacute disease leading to demyelination.

Authors:  M C Dal Canto; S G Rabinowitz
Journal:  Am J Pathol       Date:  1981-03       Impact factor: 4.307

5.  Measles encephalomyelitis--clinical and immunologic studies.

Authors:  R T Johnson; D E Griffin; R L Hirsch; J S Wolinsky; S Roedenbeck; I Lindo de Soriano; A Vaisberg
Journal:  N Engl J Med       Date:  1984-01-19       Impact factor: 91.245

6.  Coxsackievirus B-3 myocarditis. Acute and chronic forms of the disease caused by different immunopathogenic mechanisms.

Authors:  P A Lodge; M Herzum; J Olszewski; S A Huber
Journal:  Am J Pathol       Date:  1987-09       Impact factor: 4.307

7.  Coxsackievirus B-3 myocarditis in Balb/c mice. Evidence for autoimmunity to myocyte antigens.

Authors:  S A Huber; P A Lodge
Journal:  Am J Pathol       Date:  1984-07       Impact factor: 4.307

8.  Differences in cytolytic T cell response of BALB/c mice infected with myocarditic and non-myocarditic strains of coxsackievirus group B, type 3.

Authors:  S A Huber; L P Job
Journal:  Infect Immun       Date:  1983-03       Impact factor: 3.441

9.  Biological properties of an influenza A virus-specific killer T cell clone. Inhibition of virus replication in vivo and induction of delayed-type hypersensitivity reactions.

Authors:  Y L Lin; B A Askonas
Journal:  J Exp Med       Date:  1981-08-01       Impact factor: 14.307

Review 10.  Experimental models of virus-induced demyelination of the central nervous system.

Authors:  M C Dal Canto; S G Rabinowitz
Journal:  Ann Neurol       Date:  1982-02       Impact factor: 10.422

View more
  10 in total

1.  Distribution of viral RNA in the spinal cord of DBA/2 mice developing biphasic paralysis following infection with the D variant of encephalomyocarditis virus (EMC-D).

Authors:  M Takeda; R Miura; K Shiota; K Hirasawa; M J Lee; S I Itagaki; K Doi
Journal:  Int J Exp Pathol       Date:  1995-12       Impact factor: 1.925

2.  Vaccination for neuroprotection in the mouse optic nerve: implications for optic neuropathies.

Authors:  J Fisher; H Levkovitch-Verbin; H Schori; E Yoles; O Butovsky; J F Kaye; A Ben-Nun; M Schwartz
Journal:  J Neurosci       Date:  2001-01-01       Impact factor: 6.167

3.  Indirect role of T cells in development of polioencephalitis and encephalomyelitis induced by encephalomyocarditis virus.

Authors:  D J Topham; A Adesina; M Shenoy; J E Craighead; S Sriram
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

4.  Protection against lethal encephalomyocarditis virus infection in the absence of serum-neutralizing antibodies.

Authors:  Z C Neal; G A Splitter
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

5.  Encephalomyocarditis virus 2A protein is required for viral pathogenesis and inhibition of apoptosis.

Authors:  M Carocci; N Cordonnier; H Huet; A Romey; A Relmy; K Gorna; S Blaise-Boisseau; S Zientara; L Bakkali Kassimi
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

6.  Biphasic disease of central nervous system induced in DBA/2 mice by the D variant of encephalomyocarditis virus (EMC-D).

Authors:  M Takeda; S Itagaki; K Doi
Journal:  Int J Exp Pathol       Date:  1993-10       Impact factor: 1.925

7.  Picornavirus-specific CD4+ T lymphocytes possessing cytolytic activity confer protection in the absence of prophylactic antibodies.

Authors:  Z C Neal; G A Splitter
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

Review 8.  The encephalomyocarditis virus.

Authors:  Margot Carocci; Labib Bakkali-Kassimi
Journal:  Virulence       Date:  2012-06-22       Impact factor: 5.882

9.  Serendipity: Reflections on Being Mentored by Dr. Peter Doherty.

Authors:  David J Topham
Journal:  Viral Immunol       Date:  2020-04       Impact factor: 2.257

Review 10.  The virology of demyelinating diseases.

Authors:  R T Johnson
Journal:  Ann Neurol       Date:  1994       Impact factor: 10.422

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.